Last updated: February 20, 2026
What is the current state of clinical trials for Capivasertib?
Capivasertib (formerly AZD5363) is an oral AKT kinase inhibitor developed by AstraZeneca. Its clinical development primarily targets cancers with PI3K/AKT pathway aberrations, including breast, ovarian, endometrial, and prostate cancers.
Clinical trial phases
- Phase I: Completed early safety and dosage studies. Data published show manageable safety profile with common adverse effects including hyperglycemia and gastrointestinal symptoms.
- Phase II: Several trials ongoing, evaluating efficacy in specific cancer subtypes. Notably, a phase II trial with Capivasertib combined with fulvestrant in estrogen receptor-positive breast cancer demonstrated promising response rates.
- Phase III: No publicly available phase III trial results. AstraZeneca announced plan to initiate larger studies in combination regimens for breast and prostate cancers based on phase II data.
Key trials
| Trial Identifier |
Phase |
Status |
Focus |
Expected completion |
| FAKTION |
II |
Completed |
Capivasertib + fulvestrant in ER+ breast cancer |
2022 |
| PAKT |
II |
Recruiting |
Capivasertib + Paclitaxel in advanced breast cancer |
2023 |
| CAPItello-291 |
III |
Not yet started |
Capivasertib + fulvestrant vs. placebo + fulvestrant |
2024 |
Recent updates
- In March 2023, AstraZeneca published updated data indicating improved progression-free survival in ER+ breast cancer patients.
- The company is pursuing accelerated pathways for certain indications, leveraging biomarker-driven strategies.
How does Capivasertib perform in the current oncology treatment landscape?
Market context
The global oncology drug market was valued at approximately USD 180 billion in 2022. Within this, targeted therapies account for about 55%, with kinase inhibitors constituting the largest segment.
Competitive landscape
Capivasertib faces competition from:
- Alpelisib (Piqray): PI3K alpha-specific inhibitor approved for PIK3CA-mutated breast cancer.
- Ipatasertib (GDC-0068): An AKT inhibitor in late-stage clinical testing.
- Capivasertib: Differentiates through broader AKT isoform inhibition and combination potential.
Key differentiators
- Biomarker support: Efficacy appears enhanced in tumors with PTEN loss or PIK3CA mutations.
- Combination potential: Partners well with hormone therapy, chemotherapy, and immunotherapy.
Regulatory considerations
- No approved indication for Capivasertib.
- Regulatory submissions anticipated based on ongoing trial results, with potential fast-track designations for specific populations.
What is the market projection for Capivasertib?
Market size estimates
By 2027, the targeted oncology kinase inhibitor segment is projected to reach USD 75 billion, driven by monotherapy and combination regimens.
Revenue forecasts
- 2023: Early-stage commercialization or licensing deals expected, with estimated revenues below USD 100 million.
- 2025: Peak sales in select indications (such as ER+ breast cancer with specific biomarkers) could reach USD 500 million, contingent on approval and label expansion.
- 2027: Market penetration could grow further, especially if randomized phase III data solidifies efficacy, with potential revenues exceeding USD 1 billion for the approved branches.
Key drivers
- Biomarker screening capacity to identify suitable patients.
- Approval of combination protocols extending indications.
- Strategic licensing agreements with local and regional partners.
Risks
- Delays or failures in phase III trials.
- Competition from therapies with established standards.
- Regulatory hurdles and cost of payer reimbursement.
Summary table: Market forecast at a glance
| Year |
Estimated Revenue |
Key Factors |
| 2023 |
<$100 million |
Early licensing deals, initial market entry |
| 2025 |
~$500 million |
Approval for ER+ breast cancer; expanded label potential |
| 2027 |
>$1 billion |
Broader indication approvals; combination therapy adoption |
Key Takeaways
- Capivasertib demonstrates promising activity in ER+ breast cancer, especially with biomarker-driven approaches.
- Clinical development is progressing toward phase III, with regulatory submissions anticipated in the next 2 years.
- Market potential is substantial, contingent on successful trial outcomes and regulatory approvals.
- The compound’s niche lies in combination strategies targeting specific molecular profiles.
- Competitive pressures exist from other kinase inhibitors, but biomarker support and combination evidence favor Capivasertib’s positioning.
FAQs
1. What cancers are being targeted in Capivasertib trials?
Primarily breast, ovarian, endometrial, and prostate cancers with PI3K/AKT pathway mutations or loss of PTEN.
2. When might Capivasertib receive regulatory approval?
Potential approval timelines depend on upcoming phase III trial results, expected around 2024–2025.
3. How does Capivasertib compare to other AKT inhibitors?
It offers broader isoform inhibition and combination flexibility, with ongoing head-to-head or indirect comparison trials.
4. What biomarkers could influence Capivasertib’s efficacy?
PTEN loss and PIK3CA mutations are associated with improved responses.
5. What is the likelihood of market success for Capivasertib?
Dependent on positive phase III data, regulatory approval, and successful commercialization strategies in competing indications.
References
[1] AstraZeneca. (2023). Clinical trial updates for Capivasertib. Retrieved from AstraZeneca phase I-III trial registry.
[2] MarketResearch.com. (2023). Global oncology kinase inhibitor market forecasts. Specialty Reports.
[3] Food and Drug Administration (FDA). (2022). Guidelines for biomarker-based drug approvals.
[4] BioCentury. (2023). Pipeline review: Capivasertib in breast and prostate cancer. BioCentury Publications.
[5] ClinicalTrials.gov. (2023). Capivasertib study registry. National Library of Medicine.
